CA Patent

CA3090620A1 — Inhibitor of setdb1 histone methyltransferase for use in cancer combination therapy

Assigned to Institut National de la Sante et de la Recherche Medicale INSERM · Expires 2019-09-12 · 7y expired

What this patent protects

The present invention relates to an inhibitor of H3K9 histone methyl transferase SETDB1 for use in combination with at least one immune checkpoint modulator in the treatment of cancer.

USPTO Abstract

The present invention relates to an inhibitor of H3K9 histone methyl transferase SETDB1 for use in combination with at least one immune checkpoint modulator in the treatment of cancer.

Drugs covered by this patent

Patent Metadata

Patent number
CA3090620A1
Jurisdiction
CA
Classification
—
Expires
2019-09-12
Drug substance claim
No
Drug product claim
No
Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.